Cytokinetics Inc. insider trading
CYTKfinancial statementsForm 4 filings on EDGAR372 transactions since Nov 9, 2024
From August 12, 2026 to November 9, 2026, 0 insiders at Cytokinetics Inc. bought $0 of stock in the open market, and 5 sold $12M. Officers and directors accounted for $0 of purchases and $12M of sales. The last reported transaction was an option exercise by Malik Fady Ibraham on November 3, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through November 3, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $12MAug 12, 2026 – Nov 9, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Nov 6, 2026. Insider data through Nov 9, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
372 transactions from November 9, 2024 to November 9, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Malik Fady Ibraham | EVP Research & Development | option exercise | 3,500 | $7.80 | $27K | 157,402 | Nov 3, 2026 |
| Nov 3, 2026 | Malik Fady Ibraham | EVP Research & Development | open-market sale10b5-1 | 3,500 | $62.93 | $220K | 153,902 | Nov 3, 2026 |
| Nov 2, 2026 | Blum Robert I | President & CEO, Director | option exercise | 7,500 | $10.60 | $80K | 286,044 | Nov 2, 2026 |
| Nov 2, 2026 | Blum Robert I | President & CEO, Director | open-market sale10b5-1 | 7,500 | $62.81 | $471K | 278,544 | Nov 2, 2026 |
| Oct 20, 2026 | Malik Fady Ibraham | EVP Research & Development | option exercise | 3,500 | $7.80 | $27K | 157,402 | Oct 20, 2026 |
| Oct 20, 2026 | Malik Fady Ibraham | EVP Research & Development | open-market sale10b5-1 | 3,500 | $64.01 | $224K | 153,902 | Oct 20, 2026 |
| Oct 16, 2026 | Wysenski Nancy | Director | award | 97 | $63.92 | $6K | 34,089 | Oct 20, 2026 |
| Oct 16, 2026 | Kaye Edward M. MD | Director | award | 195 | $63.92 | $12K | 10,629 | Oct 20, 2026 |
| Oct 16, 2026 | Harrington Robert Arthur | Director | award | 195 | $63.92 | $12K | 22,127 | Oct 20, 2026 |
| Oct 16, 2026 | Daly James M | Director | award | 195 | $63.92 | $12K | 3,585 | Oct 20, 2026 |
| Oct 16, 2026 | Wierenga Wendell | Director | award | 97 | $63.92 | $6K | 35,660 | Oct 20, 2026 |
| Oct 16, 2026 | Henderson John T | Director | award | 352 | $63.92 | $23K | 78,712 | Oct 20, 2026 |
| Oct 12, 2026 | Blum Robert I | President & CEO, Director | option exercise | 7,500 | $10.60 | $80K | 286,044 | Oct 13, 2026 |
| Oct 12, 2026 | Blum Robert I | President & CEO, Director | open-market sale10b5-1 | 7,500 | $62.88 | $472K | 278,544 | Oct 13, 2026 |
| Oct 6, 2026 | Malik Fady Ibraham | EVP Research & Development | option exercise | 3,500 | $7.80 | $27K | 157,402 | Oct 6, 2026 |
| Oct 6, 2026 | Malik Fady Ibraham | EVP Research & Development | open-market sale10b5-1 | 3,500 | $61.38 | $215K | 153,902 | Oct 6, 2026 |
| Sep 28, 2026 | Blum Robert I | President & CEO, Director | option exercise | 7,500 | $10.60 | $80K | 286,044 | Sep 28, 2026 |
| Sep 28, 2026 | Blum Robert I | President & CEO, Director | open-market sale10b5-1 | 7,500 | $65.46 | $491K | 278,544 | Sep 28, 2026 |
| Sep 22, 2026 | Malik Fady Ibraham | EVP Research & Development | option exercise | 3,500 | $7.80 | $27K | 157,402 | Sep 22, 2026 |
| Sep 22, 2026 | Malik Fady Ibraham | EVP Research & Development | open-market sale10b5-1 | 3,500 | $68.29 | $239K | 153,902 | Sep 22, 2026 |
| Sep 15, 2026 | Landry Robert E | Director | open-market sale10b5-1 | 1,000 | $72.13 | $72K | 8,184 | Sep 15, 2026 |
| Sep 15, 2026 | Blum Robert I | President & CEO, Director | open-market sale10b5-1indirect | 97,926 | $69.33 | $7M | 0 | Sep 15, 2026 |
| Sep 14, 2026 | Blum Robert I | President & CEO, Director | option exercise | 7,500 | $10.60 | $80K | 385,320 | Sep 15, 2026 |
| Sep 14, 2026 | Blum Robert I | President & CEO, Director | open-market sale10b5-1 | 7,500 | $73.44 | $551K | 377,820 | Sep 15, 2026 |
| Sep 14, 2026 | Blum Robert I | President & CEO, Director | gift | 1,350 | $0.00 | — | 376,470 | Sep 15, 2026 |
| Sep 14, 2026 | Blum Robert I | President & CEO, Director | gift | 97,926 | $0.00 | — | 278,544 | Sep 15, 2026 |
| Sep 14, 2026 | Blum Robert I | President & CEO, Director | giftindirect | 97,926 | $0.00 | — | 97,926 | Sep 15, 2026 |
| Sep 11, 2026 | Landry Robert E | Director | open-market sale10b5-1 | 1,000 | $74.66 | $75K | 9,184 | Sep 11, 2026 |
| Sep 8, 2026 | Malik Fady Ibraham | EVP Research & Development | option exercise | 3,500 | $7.80 | $27K | 157,402 | Sep 8, 2026 |
| Sep 8, 2026 | Malik Fady Ibraham | EVP Research & Development | open-market sale10b5-1 | 3,500 | $75.46 | $264K | 153,902 | Sep 8, 2026 |
| Sep 1, 2026 | Parshall B Lynne | Director | open-market sale10b5-1 | 5,000 | $71.48 | $357K | 10,784 | Sep 1, 2026 |
| Aug 31, 2026 | Callos Andrew | EVP, Chief Commercial Officer | option exercise | 10,000 | $23.26 | $233K | 68,555 | Aug 31, 2026 |
| Aug 31, 2026 | Callos Andrew | EVP, Chief Commercial Officer | open-market sale10b5-1 | 10,000 | $70.24 | $702K | 58,555 | Aug 31, 2026 |
| Aug 31, 2026 | Blum Robert I | President & CEO, Director | option exercise | 7,500 | $10.60 | $80K | 385,320 | Aug 31, 2026 |
| Aug 31, 2026 | Blum Robert I | President & CEO, Director | open-market sale10b5-1 | 7,500 | $70.24 | $527K | 377,820 | Aug 31, 2026 |
| Aug 18, 2026 | Malik Fady Ibraham | EVP Research & Development | option exercise | 3,500 | $7.80 | $27K | 157,402 | Aug 18, 2026 |
| Aug 18, 2026 | Malik Fady Ibraham | EVP Research & Development | open-market sale10b5-1 | 3,500 | $75.82 | $265K | 153,902 | Aug 18, 2026 |
| Aug 10, 2026 | Blum Robert I | President & CEO, Director | option exercise | 7,500 | $10.60 | $80K | 385,320 | Aug 10, 2026 |
| Aug 10, 2026 | Blum Robert I | President & CEO, Director | open-market sale10b5-1 | 7,500 | $76.76 | $576K | 377,820 | Aug 10, 2026 |
| Jul 30, 2026 | Callos Andrew | EVP, Chief Commercial Officer | option exercise | 14,000 | $23.26 | $326K | 72,555 | Jul 30, 2026 |
| Jul 30, 2026 | Callos Andrew | EVP, Chief Commercial Officer | open-market sale10b5-1 | 14,000 | $79.88 | $1M | 58,555 | Jul 30, 2026 |
| Jul 27, 2026 | Blum Robert I | President & CEO, Director | option exercise | 7,500 | $10.60 | $80K | 385,320 | Jul 27, 2026 |
| Jul 27, 2026 | Blum Robert I | President & CEO, Director | open-market sale10b5-1 | 7,500 | $80.87 | $607K | 377,820 | Jul 27, 2026 |
| Jul 21, 2026 | Malik Fady Ibraham | EVP Research & Development | option exercise | 3,500 | $7.80 | $27K | 157,402 | Jul 23, 2026 |
| Jul 21, 2026 | Malik Fady Ibraham | EVP Research & Development | open-market sale10b5-1 | 3,500 | $80.59 | $282K | 153,902 | Jul 23, 2026 |
| Jul 15, 2026 | Wysenski Nancy | Director | award | 75 | $82.62 | $6K | 33,992 | Jul 16, 2026 |
| Jul 15, 2026 | Wierenga Wendell | Director | award | 75 | $82.62 | $6K | 35,563 | Jul 16, 2026 |
| Jul 15, 2026 | Kaye Edward M. MD | Director | award | 151 | $82.62 | $12K | 10,434 | Jul 16, 2026 |
| Jul 15, 2026 | Henderson John T | Director | award | 272 | $82.62 | $22K | 78,360 | Jul 16, 2026 |
| Jul 15, 2026 | Harrington Robert Arthur | Director | award | 151 | $82.62 | $12K | 21,932 | Jul 16, 2026 |
Who the insiders are
Everyone who reported a transaction since November 9, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Blum Robert I | President & CEO, Director | Nov 2, 2026 | option exercise | 286,044 | — | $18M (20) | 17 of 20 |
| Callos Andrew | EVP, Chief Commercial Officer | Aug 31, 2026 | option exercise | 68,555 | — | $16M (25) | 22 of 25 |
| Lee Sung | EVP, Chief Financial Officer | Jul 1, 2026 | option exercise | 64,333 | — | $6M (5) | 4 of 5 |
| Malik Fady Ibraham | EVP Research & Development | Nov 3, 2026 | option exercise | 157,402 | — | $5M (21) | 18 of 21 |
| Kaye Edward M. MD | Director | Oct 16, 2026 | award | 10,629 | — | $2M (3) | 3 of 3 |
| Henderson John T | Director | Oct 16, 2026 | award | 78,712 | — | $2M (2) | 2 of 2 |
| Wierenga Wendell | Director | Oct 16, 2026 | award | 35,660 | — | $2M (2) | 2 of 2 |
| Parshall B Lynne | Director | Sep 1, 2026 | open-market sale | 10,784 | — | $1M (4) | 4 of 4 |
| Landry Robert E | Director | Sep 15, 2026 | open-market sale | 8,184 | — | $147K (2) | 2 of 2 |
| Harrington Robert Arthur | Director | Oct 16, 2026 | award | 22,127 | — | $144K (1) | 1 of 1 |
| Wysenski Nancy | Director | Oct 16, 2026 | award | 34,089 | — | — | — |
| Wierenga Wendall | Director | Jul 15, 2025 | award | 32,345 | — | — | — |
| Daly James M | Director | Oct 16, 2026 | award | 3,585 | — | — | — |
| Bhanji Muna | Director | May 27, 2026 | award | 26,361 | — | — | — |
| Wong Robert | VP, Chief Accounting Officer | Dec 3, 2024 | award | 18,162 | — | — | — |
| Hessekiel Jeffrey | Chief Legal & Admin Officer | Mar 15, 2026 | award | 107,943 | — | — | — |
Questions
Are Cytokinetics Inc. insiders buying or selling?
Over the twelve months to November 9, 2026, 10 insiders at Cytokinetics Inc. sold $52M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $52M. Only open-market purchases and sales are counted.
Who sold the most Cytokinetics Inc. stock in the last year?
Blum Robert I (President & CEO, Director) sold $18M in 20 open-market sales over the twelve months to November 9, 2026.
Do Cytokinetics Inc. executives sell under 10b5-1 plans?
75 of the 85 open-market sales in the last twelve months (88%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Cytokinetics Inc.
- Cytokinetics Inc. financial statements
- 1 tracked fund holding CYTK
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.